



Acquist Therapeutics, Inc.
Essex Fells, NJ 07021

Acquist Therapeutics Expands Composition Patents for Novel Small Molecules

Drugs Developed to Treat Multiple Inflammatory Diseases

Essex Fells, NJ – November 21, 2021 – [Acquist Therapeutics, Inc.](#), a biopharmaceutical company committed to discovery of new treatments for patients with inflammatory diseases, announced that the Company has expanded patent content and coverage from its composition patents. The most recent, U.S. approved patent covers compounds that are intended to help patients with gout, NASH (nonalcoholic steatohepatitis), and other illnesses.

Compositions, uses, and claims from the U.S. application have also been filed worldwide. Among a number of ex-U.S. filings, the patent has been allowed in Japan, Korea, Canada, China, Hong Kong, India, Mexico, and other territories. Acquist expects the current patent portfolio will provide exclusivity on compositions to at least 2039.

The Company's is developing small molecules for oral once-daily dosing. Acquist intends to prioritize its initial clinical program in patients with advanced gout.

Acquist Discovery

Acquist has developed novel, potent, bifunctional inhibitors of enzymes that reduce production and promote excretion of uric acid (UA). This target is causally linked to many inflammatory diseases and is a primary initiator of gout. In NASH, elevated UA is associated with fatty liver and subsequent triggering of inflammation. In human liver cells, Acquist bifunctional drugs sharply reduce both UA and triglycerides.

About Acquist

Acquist is focused on improving health for patients with inflammatory and metabolic diseases. Acquist compounds are markedly more potent than drugs currently used for gout. A prototype drug with bifunctional activity has demonstrated exceptional clinical activity in reducing serum uric acid. In both NASH and gout, effective treatment could substantially relieve both morbidity and mortality from these progressive illnesses. Further information can be accessed at www.acquistrx.com.

SOURCE: Acquist Therapeutics, Inc.®